Objective: Sepsis is an immune response to infections that are caused by bacteria, viruses, fungi, or parasites. This potentially life-threatening condition is associated with high mortality and morbidity that causes a major global health burden and hence requires intense therapeutic support and close monitoring. As a result, substantial work has been done to enhance outcomes by focusing on alternate treatment strategies. One such approach is CytoSorb®, an extracorporeal blood purification therapy that is used for elevated cytokines levels in patients admitted to ICU suffering from sepsis and septic shock, cytokine release syndrome, COVID-19, ARDS, etc. We present authors’ experience of using CytoSorb® therapy as an adjuvant in six critically ill patients from India with sepsis or septic shock.

Patients and Methods: In this case series, we report the outcomes of six severely ill Indian adults with sepsis or septic shock who were treated by CytoSorb® as an adjuvant therapy.

Results: All patients across wide age groups demonstrated significantly reduced inflammatory mediators and vital parameters when CytoSorb® therapy was initiated within 24 hours of admission in ICU. It was also found to be effective and safe in patients with COVID-19 and associated post-COVID symptoms. The present case series showed rapid hemodynamic stability and enhanced survival in all patients except one, as a consequence of hemoadsorption utilizing CytoSorb®, especially in individuals for whom therapy was initiated early.

Conclusions: CytoSorb® treatment is efficient in cases where elevated levels of cytokines lead to hyperinflammation. It not only resolves excessive inflammation, but also improves organ dysfunction and provides further clinical benefits in severely ill patients.